pharma · Acute Myeloid Leukemia · Acute Leukemia · ATNM
Actinium Pharmaceuticals
Actinium Pharmaceuticals is a pharma organization headquartered in New York, USA. It trades on NYSE under ticker ATNM. Primary therapeutic focus areas include Acute Myeloid Leukemia, Acute Leukemia, Sickling Disorder Due
New York, USA HQ
2000 Founded
58 Employees
Public company Type
ATNM · NYSE Ticker
Company details
- Status
- Public
- HQ
- New York, USA
- Founded
- 2000
- Employees
- 58
- Programs
- 8
- Drugs
- 4
- Patents
- 20
ACTINIUM-225-LABELED HUMANIZED ANTI-CD33 MONOCLONAL ANTIBODY HuM195
Phase 1 · mab · Leukemia
ACTINIUM-225-LABELED HUMANIZED ANTI-CD33 MONOCLONAL ANTIBODY HuM195 for Leukemia is a Phase 1 program (mab) at Actinium Pharmaceuticals with 1 ClinicalTrials.gov record(s).
Internal code 02-017
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Actinium Pharmaceuticals
- Phase
- Phase 1
- Modality
- mab
- Indication
- Leukemia
- Status
- completed
- Trials
- 1